CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
Irinotecan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01091259
NCT01091259Phase 2Completed
CompareCT.gov

Phase II Study of Irinotecan in Combination With Bevacizumab for the Treatment of Recurrent Ovarian Cancer.

NYU Langone Health·interventional·Posted Mar 23, 2010·Updated Nov 24, 2015

In Brief

A Phase 2 clinical trial evaluating Irinotecan and Bevacizumab for Ovarian Cancer and 2 related conditions. Completed, enrolled 29 participants across 2 sites.

Detailed Summary

The purpose of the study is to evaluate the efficacy and toxicity of irinotecan in the treatment of women with recurrent epithelial ovarian cancer or primary peritoneal cancer when combined with bevacizumab.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
CountriesUnited States
CollaboratorsGenentech, Inc.

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 23, 2010
Enrollment StartMar 1, 2010
Primary CompletionFeb 1, 2014
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 16.3 years ago

Interventions

Irinotecandrug

Bevacizumabdrug